The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

The complete response (CR) rate at 1 month improved from 25% with single-fraction conformal 3D RT (3D-CRT) to 37% with SBRT, ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

The risk calculator shows improved precision in a population larger than the original dataset used to validate the tool.

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Bristol-Myers Squibb is getting the corporate equivalent of a polite shrug from analysts, with most advising investors to ...

1 Day BMY -3.30% DJIA -0.64% S&P 500 0.72% Health Care/Life Sciences -1.52% ...

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...